ArticleFrontiers in pediatrics2025
A case report of Behcet's disease in a child with trisomy 8 and literature review.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Report a case of Behcet's disease (BD) in a child with trisomy 8 mosaicism (T8M), providing insights for the diagnosis, treatment, and prognosis of this condition. Methods: The clinical data of an 11-year-old girl with T8M mosaicism and BD who was admitted to our hospital in August 2022 were retrospectively analyzed, and the relevant literature was reviewed. Results: The main clinical manifestations of the child were recurrent oral ulcers, vulvar ulcers, fever, and joint deformities of both hands. Inflammatory markers (CRP, white blood cell, IL-6, IL-17) were significantly increased, and complement C3 and C4 were decreased. Cranial MRI showed dysplasia of the corpus callosum and ventriculomegaly. BD was diagnosed according to the international standard, and genetic testing confirmed a karyotype of 47, XX, +8[9]/46, XX [31] (chimerism ratio 22.50%). After treatment with glucocorticoids combined with immunosuppressants (including thalidomide, etc.), the ulcer and inflammatory markers were rapidly relieved. However, the ulcer recurred two and a half years after drug withdrawal. Conclusions: T8M may be detected in the autoinflammatory stage of BD, before any overt hematologic manifestations appear. Children presenting with BD-like features plus developmental anomalies or refractory autoinflammation should undergo karyotyping to establish the presence or absence of T8M, thereby informing both clinical management and genetic counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.